Canopy(1) | $22,000,000 | (Jan 13, 2026)
Onsetto | $2,200,000 | (Jan 13, 2026)
BlueNalu | $11,000,000 | (Jan 13, 2026)
Certified by Founder
Lodge
Angitia Biopharmaceuticals
start up
United States
- Woodland Hills, CA
- 12/12/2024
- Series C
- $120,000,000
Angitia is a clinical-stage biotechnology company focused on discovering and developing breakthrough therapeutics that address the key unmet medical needs of serious musculoskeletal diseases. With the team’s experience and scientific expertise in new drug development, Angitia is dedicated to bringing innovative therapeutics to help patients in need.
- Industry Biotechnology Research
- Website https://www.angitiabio.com/
- LinkedIn https://www.linkedin.com/company/angitia-biopharmaceuticals/
Related People
Hua Zhu (David) KeFounder
United States -
Greater Los Angeles, California
Discovery and translational research professional, specifically in bone and renal diseases.
Cytotheryx, Inc. | $60,000,000 | (Jan 13, 2026)
MEDIPOST, Inc. | $140,000,000 | (Jan 13, 2026)
TRYBE | $30,000,000 | (Jan 13, 2026)
Kinaset Therapeutics | $103,000,000 | (Jan 13, 2026)
Diagonal Therapeutics | $125,000,000 | (Jan 13, 2026)
VelaFi | $20,000,000 | (Jan 13, 2026)
encoord | $2,000,000 | (Jan 13, 2026)
Vibrant Therapeutics | $61,000,000 | (Jan 13, 2026)
Avenue Biosciences | $7,500,000 | (Jan 13, 2026)
Unusual | $3,600,000 | (Jan 13, 2026)